Bioventix risk profile
35 Normal where most of the sector sits
Measured 1 September 2026 from BVXP's filed statements. Recomputed nightly.
35 (Normal), driven by Market expectation at 59, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 59 | Elevated | Stable | One-year price volatility — 42.3% |
| Operating pressure | 52 | Elevated | Worsening | Costs outgrowing revenue — +5.7 percentage points |
| Cash conversion | 26 | Normal | Stable | Cash conversion — 0.93x |
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 24 | Normal | Stable | Revenue-growth gap against peers — -4.6 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.